EFFICACY OF SOLIFENACIN FOR TREATMENT OF OVERACTIVE BLADDER IN WOMEN

S JEHAN; SU REHMAN; A HAYAT; A WAHAB; M IZHAR

doi:10.54112/bcsrj.v2024i1.1476

Authors

S JEHAN MMC General Hospital, Peshawar, Pakistan
SU REHMAN Muhammad Teaching Hospital, Peshawar, Pakistan
A HAYAT Institute of Kidney Diseases Peshawar, Pakistan
A WAHAB Institute of Kidney Diseases Peshawar, Pakistan
M IZHAR Institute of Kidney Diseases Peshawar, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1476

Keywords:

Efficacy, Overactive Bladder, Solifenacin

Abstract

Overactive bladder (OAB) significantly affects the quality of life in women due to symptoms such as urgency, increased frequency, and incontinence. Solifenacin, a muscarinic receptor antagonist, has been widely used to treat OAB, but its efficacy needs further validation in diverse populations. Objective: To determine solifenacin's efficacy for treating overactive bladder in women. Descriptive Case Series Department of Urology, Institute of Kidney, from 1st January 2023 to 30th June 2023.Methods: Seventy-seven female patients with overactive bladder diagnosed by consultant urologist on clinical presentation were included in this study. The WHO Sample Size calculator calculated the sample size with 92.20% efficacy of solifenacin, 80% power of the test, and 5% significance level. Clinical evaluation was done, and the baseline severity of symptoms was recorded. Baseline severity was defined according to the number of incontinence episodes/24 h, number of urgency episodes/24 h, and micturition frequency/24 h. Patients were advised of solifenacin 5 mg OD for twelve weeks. Patients were followed up in the twelfth week, and efficacy was determined regarding improvement in the severity of OAB symptoms, i.e., improvement of at least 03 points from the baseline. Results: As per the efficacy of Solifenacin in treating OAB symptoms, 37 (86.0%) showed effective results. Conclusion: Solifenacin showed significant effectiveness in terms of improvement in the severity of OAB symptoms in female patients.

Downloads

Download data is not yet available.

References

Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: Evaluation and management. Curr Urol. 2018;11:117–125.

Scarneciu I, Lupu S, Bratu OG, Teodorescu A, Maxim LS, Brinza A, Laculiceanu AG, Rotaru RM, Lupu AM, Scarneciu CC. Overactive bladder: A review and update. Exp Ther Med. 2021 Dec;22(6):1444.

Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48:5–26.

Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, Roach M, Miklos J, Saltzstein D, Boone T, Staskin DR, Albrecht D. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358–363.

Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 2001;57:414–421.

Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, Kell SH. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–695.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int. 2010;105:58–66.

Robinson D, Cardozo L. Antimuscarinic drugs to treat overactive bladder. BMJ. 2012;344:e2130.

Oresković S, But I, Banović M, Goldstajn MS. The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Coll Antropol. 2012 Mar;36(1):243-8.

Hung MJ, Chou CL, Yen TW, Chuang YC, Meng E, Huang ST, et al. Development and validation of the Chinese overactive bladder symptom score for assessing overactive bladder syndrome in a RESORT study. Journal of the Formosan Medical Association. 2013; 112(5):276-82.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. Onabotulinumtoxin A 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomized, double-blind, placebo-controlled trial.European Urology. 2013; 64(2):249-56.

Yamada S, Ito Y, Nishijima S, Kadekawa K, Sugaya K. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacology & Therapeutics. 2018; 189:130-48.

Smith AL, Wein AJ. Antimuscarinic pharmacotherapy for overactive bladder. Contemporary Pharmacotherapy of Overactive Bladder: Springer; 2019. p. 85-113.

Nambiar AK, Bosch R, Cruz F, Lemack GE, Thiruchelvam N, Tubaro A, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. European Urology. 2018; 73(4):596-609.

Tailor VK, Digesu GA. Overactive bladder. Postmenopausal diseases and disorders: Springer; 2019. p. 133-44.19. Eapen RS, Radomski SB. Review of the epidemiology of overactive bladder. Research and Reports in Urology. 2016; 8:71.

Nalliah S, Gan PW, Masten Singh PK, Naidu P, Lim V, Ahamed AA. Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.Australian Family Physician. 2017; 46(3):139.

Basra R, Kelleher C. A review of solifenacin in the treatment of urinary incontinence. Therapeutics and Clinical Risk Management. 2008; 4(1):117.22. Kakar H, Kok B, Mokhles S, Sarwar M. Comparison of festerodine, tolterodine, oxybutyinin and solifenacin in patients with overactive bladder. Erasmus J Med. 2012; 2(2):20-4.

Kakar H, Kok B, Mokhles S, Sarwar M. Comparison of festerodine, tolterodine, oxybutyinin and solifenacin in patients with overactive bladder. Erasmus J Med. 2012; 2(2):20-4.